Aging in the blood-forming system is often described as a broad decline: stem cells become less regenerative, immune-cell production shifts, and abnormal clones gain ground. Two studies published this week suggest a more useful model. The stem-cell pool separates into biologically different factions, while the bone-marrow environment can be remodeled to favor cells carrying age-associated mutations.
The papers, published in The EMBO Journal on August 5 and Nature Cell Biology on August 6, examine different parts of the same system. One maps early differences among hematopoietic stem cells, which generate the body’s blood and immune cells. The other tests how mutant blood cells alter neighboring support cells in the marrow. Together, they frame aging as a problem of selection and feedback, not simply a synchronized loss of function.
An early split inside the stem-cell pool
In The EMBO Journal, researchers led from the Chinese Academy of Medical Sciences and Peking Union Medical College focused on P-selectin, a surface protein also known as SELP or CD62P. Their analysis of previously generated human single-cell data covered stem cells from donors grouped as young adults, middle-aged adults and older adults. P-selectin expression rose by middle age and remained elevated in older cells.
That signal did not mark every cell equally. Human stem cells with higher SELP expression carried gene-expression patterns associated with inflammation, oxidative stress, DNA damage and a shift toward megakaryocyte and myeloid lineages. Cells with lower expression retained patterns linked to redox balance, metabolism and lymphoid potential. These are molecular associations in human samples; they do not show that P-selectin causes aging in people.
The team then tested function in mice. In animals at an early-aging stage, P-selectin-high stem cells showed poorer long-term repopulation after transplantation and more myeloid-skewed output than P-selectin-low cells. The investigators also used an inflammatory challenge and chromatin-accessibility analysis to connect the high-expression state with stress-responsive regulatory programs. Those experiments strengthen the biological case, but transplantation and experimentally induced inflammation are not the same as ordinary human aging.
The marrow niche can reward mutant cells
The Nature Cell Biology study, led by researchers at The Jackson Laboratory, examined clonal hematopoiesis. In that condition, a blood stem cell with an acquired mutation expands into a larger clone. Clonal hematopoiesis becomes more common with age and can raise the risk of blood cancers and other disease, although many people who carry such clones never progress to malignancy.
Using a mouse model with a mutation in Dnmt3a, a gene frequently altered in clonal hematopoiesis, the researchers found that mutant blood cells changed mesenchymal stromal cells in the surrounding marrow. The stromal cells entered a senescence-like molecular state after exposure to soluble inflammatory signals that included TNF-alpha and IL-6. The study identified STAT3 signaling as a necessary part of that response.
The group also observed elevated stromal-cell senescence in human marrow samples associated with several common clonal-hematopoiesis mutations. The causal intervention, however, remained preclinical: genetically or pharmacologically depleting senescent non-blood cells reduced the mutant-clone burden and delayed myeloproliferative disease in mice. The work does not establish a preventive treatment for people, nor does it show that clearing senescent cells broadly would be safe or beneficial.
TENS analysis: aging as an ecosystem
Read together, the studies shift the unit of analysis from an average aging stem cell to a competitive ecosystem in which cell state and neighborhood reinforce one another. P-selectin may help distinguish more vulnerable from more resilient stem cells, while mutant clones may reshape their surroundings to improve their own fitness.
That distinction matters because a marker can identify vulnerability without proving that blocking the marker will restore function. P-selectin participates in normal cell adhesion and inflammatory biology, and the marrow-niche study shows that the same broad process called senescence can have context-dependent effects. A strategy aimed at one cell type, signal or time point could behave differently elsewhere in the blood system.
The cross-study comparison also clarifies what future evidence must resolve. Researchers need prospective human studies to learn whether P-selectin-defined states predict immune decline or clonal expansion over time. They also need to establish whether the stromal feedback loop appears before a clone becomes clinically consequential, and whether it can be interrupted without damaging normal blood formation.
The near-term value is therefore not an anti-aging treatment but a sharper research map: identify which cells are changing, determine whether the change is a cause or a consequence, and measure how the surrounding tissue alters the competition. That is a narrower claim than rejuvenation, but it is a more testable path toward preserving blood and immune function with age.
Sources: The EMBO Journal; Nature Cell Biology.
TENS Magazine conceptual illustration
